Summers Healthcare, Llc in Okeene, OK

Summers Healthcare, Llc is a medicare and medicaid certified nursing home in Okeene, Oklahoma. It is located in Blaine county at 119 North 6th Street, Okeene, Oklahoma 73763. You can reach out to the office of Summers Healthcare, Llc via phone at (580) 822-4441. This skilled nursing facility has 48 federally certified beds with average occupancy rate of 51.67%. Its legal business name is Summers Health Services, Llc and has the following ownership type - For Profit - Individual.

Summers Healthcare, Llc (Medicare CCN 375478) is certified by CMS (Centers for Medicare & Medicaid Services) and participates in both medicare and medicaid program. This means if you are part of medicare or medicaid program, you may consider this nursing facility for your medical needs. It was first certified by CMS in 2004 (20 years certified) and the last quality survey was conducted in September, 2019.

Contact Information

Summers Healthcare, Llc
119 North 6th Street, Okeene, Oklahoma 73763
(580) 822-4441


Nursing Home Profile

NameSummers Healthcare, Llc
Location119 North 6th Street, Okeene, Oklahoma
Certified ByMedicare and Medicaid
No. of Certified Beds48
Occupancy Rate51.67%
Medicare ID (CCN)375478
Legal Business NameSummers Health Services, Llc
Ownership TypeFor Profit - Individual

NPI Associated with this Nursing Home:

Nursing Homes may have multiple NPI numbers. We have found possible NPI number/s associated with Summers Healthcare, Llc from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.

NPI Number1114220191
Organization NameSUMMIT HEALTHCARE RECEIVERSHIP LLC
Address119 N. 6th, Okeene, OK 73763
Phone Number580-822-4441

News Archive

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Antigenics today announced that the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New Orleans, LA.

MAA for naproxcinod submitted to EMEA through centralized procedure

NicOx S.A. today announced that a Marketing Authorization Application (MAA) for naproxcinod has been submitted to the European Medicines Agency (EMEA) through the centralized procedure, seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA).

New NIH funding to help researchers explore promising new approaches to cure stroke

Dr. Gregory Bix, Paul G. Blazer J. Professor of Stroke Research in the University of Kentucky Sanders-Brown Center on Aging and the UK departments of Anatomy and Neurobiology and Neurology, has received funding of $224,416 from the National Institutes of Health, to further study of stroke recovery.

Surgeon's learning curve linked to fatality rates of oesophageal cancer patients

According to a major Swedish cohort study from researchers at Karolinska Institutet in Sweden and Imperial College London, a surgeon who operates on oesophageal cancer must have performed 60 operations to prevent any lack of experience adversely affecting the long-term survival of the patients. The finding, which is published in the Journal of Clinical Oncology, has potential significance for clinical practice.

Read more Medical News

› Verified 1 days ago


NPI Number1467843177
Organization NameSUMMERS HEALTH SERVICES, LLC
Address119 N. 6th St, Okeene, OK 73763
Phone Number580-822-4441

News Archive

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Antigenics today announced that the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New Orleans, LA.

MAA for naproxcinod submitted to EMEA through centralized procedure

NicOx S.A. today announced that a Marketing Authorization Application (MAA) for naproxcinod has been submitted to the European Medicines Agency (EMEA) through the centralized procedure, seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA).

New NIH funding to help researchers explore promising new approaches to cure stroke

Dr. Gregory Bix, Paul G. Blazer J. Professor of Stroke Research in the University of Kentucky Sanders-Brown Center on Aging and the UK departments of Anatomy and Neurobiology and Neurology, has received funding of $224,416 from the National Institutes of Health, to further study of stroke recovery.

Surgeon's learning curve linked to fatality rates of oesophageal cancer patients

According to a major Swedish cohort study from researchers at Karolinska Institutet in Sweden and Imperial College London, a surgeon who operates on oesophageal cancer must have performed 60 operations to prevent any lack of experience adversely affecting the long-term survival of the patients. The finding, which is published in the Journal of Clinical Oncology, has potential significance for clinical practice.

Read more Medical News

› Verified 1 days ago

Quality Ratings:

Nursing homes vary in the quality of care and services they provide to their residents. The below quality ratings for Summers Healthcare, Llc are calculated from three sources - health inspection results, staffing data, and quality measure data. This information gives you an indication of the care Summers Healthcare, Llc give to their patients.
Ratings from Surveys (Inspections):
Ratings from Quality Measures:
Ratings from Staffing Data:
Overall Rating:

News Archive

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Antigenics today announced that the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New Orleans, LA.

MAA for naproxcinod submitted to EMEA through centralized procedure

NicOx S.A. today announced that a Marketing Authorization Application (MAA) for naproxcinod has been submitted to the European Medicines Agency (EMEA) through the centralized procedure, seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA).

New NIH funding to help researchers explore promising new approaches to cure stroke

Dr. Gregory Bix, Paul G. Blazer J. Professor of Stroke Research in the University of Kentucky Sanders-Brown Center on Aging and the UK departments of Anatomy and Neurobiology and Neurology, has received funding of $224,416 from the National Institutes of Health, to further study of stroke recovery.

Surgeon's learning curve linked to fatality rates of oesophageal cancer patients

According to a major Swedish cohort study from researchers at Karolinska Institutet in Sweden and Imperial College London, a surgeon who operates on oesophageal cancer must have performed 60 operations to prevent any lack of experience adversely affecting the long-term survival of the patients. The finding, which is published in the Journal of Clinical Oncology, has potential significance for clinical practice.

Read more Medical News

› Verified 1 days ago

Complaints, Fines and Penalties:

Number of Facility Reported Incidents0
Number of Substantiated Complaints0
Number of Fines1
Total Amount of Fines in Dollars$650
Number of Payment Denials0
Total Number of Penalties1

Patients' Stay Experience:

The resident survey data of Summers Healthcare, Llc is compared against the national average with the color code indicators: Better than National Average Worse than National Average

Experience MeasureProviderNational Avg.
Percentage of long-stay residents whose need for help with daily activities has increased9.0914.46
Percentage of long-stay residents who lose too much weight4.855.51
Percentage of low risk long-stay residents who lose control of their bowels or bladder53.4948.41
Percentage of long-stay residents with a catheter inserted and left in their bladder01.79
Percentage of long-stay residents with a urinary tract infection4.462.65
Percentage of long-stay residents who have depressive symptoms1.095.05
Percentage of long-stay residents who were physically restrained00.23
Percentage of long-stay residents experiencing one or more falls with major injury3.573.36
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine10093.87
Percentage of long-stay residents who received an antipsychotic medication15.1514.2